BioCentury | Sep 12, 2016
Clinical News

Viaskin rPT: Phase I started

...given 2 weeks apart in about 60 healthy adults. Subjects will receive 1 dose of Boostrix...
BioCentury | Jul 18, 2011
Clinical News

Boostrix regulatory update

...FDA approved an sBLA for GlaxoSmithKline's Boostrix to prevent tetanus, diphtheria and pertussis in subjects ages...
...the indication in subjects 10-64 years of age. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Boostrix...
BioCentury | Apr 5, 2010
Company News

GlaxoSmithKline sales and marketing update

...hepatitis A virus (HAV) and HBV combination vaccine; Havrix HAV vaccine; Engerix-B HBV vaccine; and Boostrix...
BioCentury | Mar 30, 2010
Company News

GSK begins vaccine access program

...Twinrix against hepatitis A virus (HAV) and HBV; Havrix against HAV; Engerix-B against HBV; and Boostrix...
BioCentury | Aug 29, 2008
Politics & Policy

CDC releases pre-teen vaccine PSAs

...by HPV. Merck (NYSE:MRK) markets Gardasil HPV vaccine in the U.S. GlaxoSmithKline (LSE:GSK; NYSE:GSK) markets Boostrix...
BioCentury | Aug 20, 2007
Regulation

Watchdog rebuffed on Gardasil

..."generally well-tolerated across all studies." Cervarix is in a Phase III trial co-administered with GSK's Boostrix...
BioCentury | Oct 24, 2005
Clinical News

Boostrix infectious data

...trial in 2,781 healthy volunteers, Boostrix was 92% effective in protecting at-risk adolescents and adults. Boostrix...
...and Boostrix to prevent tetanus, diphtheria and pertussis. GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K. Product: Boostrix...
BioCentury | Jun 11, 2005
Company News

FDA approves Adacel vaccine

...adolescents and adults ages 11-64. The diphtheria, tetanus and acellular pertussis (DtaP) vaccine, along with Boostrix...
...advisory committee in March ( see BioCentury Extra, Tuesday March 15, 2005 ). Last month, Boostrix...
BioCentury | May 9, 2005
Clinical News

Boostrix regulatory update

...FDA approved a BLA for Boostrix, a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis booster...
...bacterial infetions in individuals aged 10 to 18. GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K. Product: Boostrix...
BioCentury | Mar 21, 2005
Clinical News

Boostrix regulatory update

...FDA's Vaccines and Related Biological Products Advisory Committee unanimously recommended approval for Boostrix tetanus toxoid, reduced...
...acellular pertussis booster vaccine for children ages 10-18. GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K. Product: Boostrix...
Items per page:
1 - 10 of 13